Zobrazeno 1 - 10
of 18
pro vyhledávání: '"329"'
Autor:
A Rios, JM Rodriguez-Fernandez, Rocío Parody, M Morey, Ayats R, Rozman C, Emili Montserrat, T Vallespi, Prados D, F Gomis
Publikováno v:
Blood. 64(3)
In previous studies, the prognostic value of bone marrow (BM) histologic patterns in chronic lymphocytic leukemia (CLL) has been demonstrated. In order to investigate whether such a value is independent of other prognostic parameters, a multivariate
Autor:
Alok A. Khorana, Fahrettin Covut, Yihong Zhou, Shafia Rahman, Shab E Gul Rahim, Sudha Amarnath
Publikováno v:
Blood. 132:1242-1242
Background:Venous thromboembolism (VTE) is a highly prevalent complication of cancer and its treatment and is commonly treated with anticoagulation1. However, there are limited data regarding the use of therapeutic anticoagulation in patients with br
Autor:
Auro Viswabandya, Hans A. Messner, Dennis Dong Hwan Kim, Jieun Uhm, Marc Poch Martell, Elizabeth Shin, Jeffrey H. Lipton, Fotios V. Michelis
Publikováno v:
Blood. 126:3139-3139
Introduction: Chronic graft versus host disease (cGVHD) is one of the major complications after allogeneic hematopoietic cell transplantation (allo-HCT). Several prognostic factors have been proposed to predict the outcomes of cGVHD including progres
Publikováno v:
Blood. 110:1310-1310
Syk kinase is central to FcR and B-cell signaling in inflammatory cells. By inhibiting syk, and thereby IgG signaling, R788 (a small molecule prodrug for biologically active R406), inhibits the downstream activation of mast cells, macrophages and B-c
Autor:
Jian-Ping Zhang, Rui-Juan Sun, Peihua Lu, Junfang Yang, Xian Zhang, Yan-Li Zhao, Jingjing Li, Min Xiong, Jia-Rui Zhou, De-Yan Liu, Yue Lu, Xing-Yu Cao, Zhi-Jie Wei
Publikováno v:
Blood. 136:40-41
Introduction Current available treatments are limited once patients with B-ALL relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT). While chimeric antigen receptor (CAR) T-cell therapy offers a chance of remission, long-t
Publikováno v:
Blood. 136:14-15
Introduction: Management of acute venous thromboembolism (VTE) in patients with chronic liver diseases is challenging due to the risk of bleeding and thrombotic complications. No clinical trials have studied vitamin K antagonists (VKA) or low molecul
Autor:
Erin Morris, John S. Holcenberg, F. Leonard Johnson, Stanton Goldman, Raymond J. Hutchinson, Jerry Z. Finklestein, Susan G. Kreissman, Elizabeth Harvey, Conrad Tou, Mitchell S. Cairo
Publikováno v:
Blood. 97:2998-3003
Standard therapy in the United States for malignancy-associated hyperuricemia consists of hydration, alkalinization, and allopurinol. Urate oxidase catalyzes the enzymatic oxidation of uric acid to a 5 times increased urine soluble product, allantoin
Autor:
Mark D. Fleming, David P. Steensma, Vilmarie Rodriguez, Shakila P. Khan, Leah A. Schmelkin, Mrinal M. Patnaik, Naseema Gangat, Matthew T. Howard, Alexandra P. Wolanskyj
Publikováno v:
Blood. 126:3355-3355
Background: Ring sideroblasts (RS) are erythroid precursors with perinuclear mitochondrial iron accumulation seen in clonal disorders, such as myelodysplastic syndromes (MDS), and non-clonal conditions, including copper deficiency, lead poisoning, an
Autor:
Nicola Vianelli, Francesca Palandri, Margherita Perricone, Massimo Breccia, Nicola Polverelli, Roberto Latagliata, Emanuela Ottaviani, Michele Cavo, Giuseppe A. Palumbo, Lucia Catani, Giuliana Alimena, Francesco Merli, Giovanni Martinelli, Alessia Tieghi
Publikováno v:
Blood. 126:1614-1614
Introduction It is acknowledged that an accurate histological diagnosis may distinguish Essential Thrombocythemia (ET) from early Primary Myelofibrosis (early-PMF), which is projected to worse outcome in terms of survival and disease evolution into a
Autor:
Lucia Masarova, Taghi Manshouri, Sherry Pierce, Prithviraj Bose, Naveen Pemmaraju, Srdan Verstovsek, Naval Daver, Hagop M. Kantarjian, Jorge E. Cortes
Publikováno v:
Blood. 126:4069-4069
Introduction: Clinical characteristics of post-essential thrombocythemia/polycythemia vera myelofibrosis "post ET/PV-MF" are not well defined as for primary myelofibrosis "MF". Objective: We aimed to identify morphological, clinical and prognostic ch